Literature DB >> 17950840

Prosthetic heart valves: catering for the few.

Peter Zilla1, Johan Brink, Paul Human, Deon Bezuidenhout.   

Abstract

Prosthetic heart valves epitomize both the triumphant advance of cardiac surgery in its early days and its stagnation into a retrospective, exclusive first world discipline of late. Fifty-two years after the first diseased heart valve was replaced in a patient, prostheses largely represent the concepts of the 1960s with many of their design-inherent complications. While the sophisticated medical systems of the developed world may be able to cope with sub-optimal replacements, these valves are poorly suited to the developing world (where the overwhelming majority of potential valve recipients reside), due to differences in age profiles and socio-economic circumstances. Therefore, it is the latter group which suffered most from the sluggish pace of developments. While it previously took less than 7 years for mechanical heart valves to develop from the first commercially available ball-in-cage valve to the tilting pyrolytic-carbon disc valve, and another 10 years to arrive at the all-carbon bi-leaflet design, only small incremental improvements have been achieved since 1977. Similarly, bioprosthetic valves saw their last major break-through development in the late 1960s when formalin fixation was replaced by glutaraldehyde cross linking. Since then, poorly understood so-called 'anti-calcification' treatments were added and the homograft concept rediscovered under the catch-phrase 'stentless'. Still, tissue valves continue to degenerate fast in younger patients, making them unsuitable for developing countries. Yet, catheter-delivered prostheses almost exclusively use bioprosthetic tissue, thereby reducing one of the most promising developments for patients of the developing world into a fringe product for the few first world recipients. With tissue-engineered valves aiming at the narrow niche of congenital malformations and synthetic flexible leaflet valves being in their fifth decade of low-key development, heart valve prostheses seem to be destined to remain an unsatisfying and exclusive first world solution for a long time to come.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17950840     DOI: 10.1016/j.biomaterials.2007.09.033

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  37 in total

1.  Need for new materials, biofunctionalization and non-surgical heart valve technology.

Authors:  Jan Sochman
Journal:  World J Cardiol       Date:  2010-03-26

Review 2.  Valvular heart diseases in the developing world: developmental biology takes center stage.

Authors:  Emily J Farrar; Jonathan T Butcher
Journal:  J Heart Valve Dis       Date:  2012-03

Review 3.  EMT-inducing biomaterials for heart valve engineering: taking cues from developmental biology.

Authors:  M K Sewell-Loftin; Young Wook Chun; Ali Khademhosseini; W David Merryman
Journal:  J Cardiovasc Transl Res       Date:  2011-07-13       Impact factor: 4.132

4.  Reynolds shear stress for textile prosthetic heart valves in relation to fabric design.

Authors:  David L Bark; Atieh Yousefi; Marcio Forleo; Antoine Vaesken; Frederic Heim; Lakshmi P Dasi
Journal:  J Mech Behav Biomed Mater       Date:  2016-02-06

5.  Fixation of Bovine Pericardium-Based Tissue Biomaterial with Irreversible Chemistry Improves Biochemical and Biomechanical Properties.

Authors:  H Tam; W Zhang; D Infante; N Parchment; M Sacks; N Vyavahare
Journal:  J Cardiovasc Transl Res       Date:  2017-02-17       Impact factor: 4.132

Review 6.  Tissue engineering on matrix: future of autologous tissue replacement.

Authors:  Benedikt Weber; Maximilian Y Emmert; Roman Schoenauer; Chad Brokopp; Laura Baumgartner; Simon P Hoerstrup
Journal:  Semin Immunopathol       Date:  2011-01-29       Impact factor: 9.623

Review 7.  How to make a heart valve: from embryonic development to bioengineering of living valve substitutes.

Authors:  Donal MacGrogan; Guillermo Luxán; Anita Driessen-Mol; Carlijn Bouten; Frank Baaijens; José Luis de la Pompa
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-03       Impact factor: 6.915

8.  Transforming growth factor β, bone morphogenetic protein, and vascular endothelial growth factor mediate phenotype maturation and tissue remodeling by embryonic valve progenitor cells: relevance for heart valve tissue engineering.

Authors:  Yung-Nung Chiu; Russell A Norris; Gretchen Mahler; Andrew Recknagel; Jonathan T Butcher
Journal:  Tissue Eng Part A       Date:  2010-07-14       Impact factor: 3.845

9.  Bovine Pericardium of High Fibre Dispersion Has High Fatigue Life and Increased Collagen Content; Potentially an Untapped Source of Heart Valve Leaflet Tissue.

Authors:  Alix Whelan; Elizabeth Williams; David R Nolan; Bruce Murphy; Paul S Gunning; David O'Reilly; Caitríona Lally
Journal:  Ann Biomed Eng       Date:  2020-10-15       Impact factor: 3.934

10.  Bone Morphogenetic Protein Signaling Is Required for Aortic Valve Calcification.

Authors:  M Victoria Gomez-Stallons; Elaine E Wirrig-Schwendeman; Keira R Hassel; Simon J Conway; Katherine E Yutzey
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-05-19       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.